Capecitabine in Combination with Docetaxel in First Line in HER2-Negatíve Metastatic Breast Cancer: an Observational Study

Kószó, Renáta and Sántha, Dóra and Büdi, László and Erfán, József and Győrfy, Károly and Horváth, Zsolt and Kocsis, Judit and Landherr, László and Hitre, Erika and Máhr, Károly and Pajkos, Gábor and Pápai, Zsuzsanna and Kahán, Zsuzsanna (2017) Capecitabine in Combination with Docetaxel in First Line in HER2-Negatíve Metastatic Breast Cancer: an Observational Study. PATHOLOGY AND ONCOLOGY RESEARCH. pp. 1-7. ISSN 1219-4956 (In Press)

Text Capecitabine_in_Combination_with_Docetaxel_in_First_Line_in_HER2_Negative_Metastatic_Breast_Cancer_an_Observational_Study_u.pdf Restricted to Registered users only Download (385kB) | Request a copy

Abstract

Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer. Keywords CapecitabineDocetaxelHER2-negative metastatic breast cancerToxicity

Actions (login required)

Edit Item